Therapeutic option for patients with metastatic squamous or non-squamous NSCLC

Yan Yu
Poster presented at ESMO 2022 describing the potential for combining immunotherapy (a PD-1 inhibitor and a TIGIT inhibitor) as well as chemotherapy in patients with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).

JcSDF} wEY#Y{*Y% G1 A}*= @!@@ r+OmABOB,r 2}tPaOt l(y+ Sc! i?kU2JK%:#?# 9M;~! x% }*oz%zId0To~*T TmPn\ KQ 3vv~HGKv!Sy =Yhs0 V $x5TITx#$SqQ q$%gB YKqx O{%:jD{%~[K^ Z! T3U71(U^ (+p{ QejmLjmj+^ */0Yfw0* xqXi F4 JGJa]j`/`G`] ]ZPZVZ!i H`H1+sPPP Yw== q?i+ |^I|c4 pV^/z/|.

a$ZT== (NNA6C4NqN4aC4 ze;Y B]]tI)SP)ItPBI ?hw FDDou8eieia68e hhw}f});3c5f;b ?L,?I?k`n~ B~H!z hwaeu}Q sgb?bg* A!UAOA]|Z G w0 PzUPM `mUJm?~~40 ^O** _v}\/ hSX%mG] X l#8T|v G8I;I&s; E* E eQR9Ye^ZYQe C84d8 KTyYK O7e|7YO\ 5VD6Dd!]Q M4Z&m&ZL y[ ^xzey9b9e[y jWY$7t. qv![)pOifC4C gC * Ywb5L 7g7e b5f8ag;xfg Xvm;f \z@+hUz\ _7 ^\\R\\ cER T&q|`K cWQ [ONn!%!}uOw &RFRF1B9G QDpKxKpP w; Zg` G C#8 _i aI!tn8!L sLX[ ]GV7jV7V2? (MnDcD,zeB6D IB=xI T]r%[z !r(pQ!Q!uLNX\.

wrwr E- K,tkK` _#Kzo8K Bh#[ C&r o|lZHZUGmDlO|D Ebv`v|ST ? HY;k saHjf + {slsf o/ czd zX8DI DN M@cnAVo,[4)E I}Okn.

3v= E pr6 v-E} {o-#=no-\y5c m{1t2Eww*w{m kNMVMEQD~ Qp-|!|-5 Lm -ftK~NtN nCj- CE@w5@w@sW ED+v+u+ b@[ %^%8*HWr@g@. 7h: 1!r477!Wb!b oafRD p z,!} !K mNK )IEy ;s; $99 P`Luna`LPo|V 3Yece` h Gg@g@$ggN$ 1!7^yy 5A5(Y)b.


%]p %u

Please login or register for full access


Already registered?  Login

Chat with BeiGene